Regeneron Invest Information

Pharmaceuticals
Dupixent® (dupilumab) Receives U.S. Approval for Treating Chronic Rhinosinusitis with Nasal Polyps in Adolescents Sep 14, 2024
Pharmaceuticals
Regeneron Showcases Respiratory Treatments at ERS 2024 Congress Aug 26, 2024
Pharmaceuticals
Innovative COPD Therapy Dupixent Gains Approval in the EU, Marking a First for Targeted Treatment Jul 4, 2024
Investment
Intellia Therapeutics Surpasses Q3 Earnings Expectations and Announces Progress in Gene-Editing Pipeline Nov 11, 2023